Site Map

Pages

• About Us
  • Leadership
• Biotech Showcase
• Contact Us
  • Careers
• Contract Manufacturing Facility
• CR845 Advances to Phase 2b in Chronic Pain
• Differentiate By Being Specific
• Download a Publication
• Download Corporate Overview Presentation
• Download Peptelligence® Brochure
• Enteris BioPharma and Cara Therapeutics’ CR845
• Enteris BioPharma and Tarsa Therapeutics’ TBRIA
• Enteris BioPharma Enhances Executive Leadership Team
• Enteris BioPharma Initiates Clinical Program for Tobrate™
• Enteris BioPharma to Present at BIO 2017
• Enteris BioPharma to Present at BioPharm America
• Enteris BioPharma to Present at Biotech Showcase 2019
• Enteris Doses First Woman in Phase 2a Clinical Trial for Endometriosis
• Enteris President & CFO to Present at Future Leaders
• Enteris to Present at BioCentury’s Future Leaders
• Enteris, KeyBioscience to Develop Solution for Metabolic Disorders
• Enteris, Sanofi to Develop Oral Therapeutic for Type 2 Diabetes
• Expanded Trial for Endometriosis Initiated
• Ferring Continues Peptide Development With Enteris
• Ferring, Enteris to Develop Oral Peptide Therapeutic
• First Patient Dosed in Phase 1 Trial of Oral (CR845) KORSUVA™
• First Patient Dosed in Trial of Oral KORSUVA™
• Formulation Technology
• Home
• News & Events
  • Press Releases
  • Articles
  • Press Coverage
• Nordic BioScience
• Oral Peptide Delivery Technology
• Partnering
• Peptelligence®-Tech and Cara’s CR845 Enters Phase 1 Trial
• Peptelligence^®
  • Oral Drug Delivery Mechanism
  • Clinical Trial Oral Drug Delivery Services
  • Oral Drug Delivery Publications
• Pipeline
  • Ovarest^®
  • Tobrate^™
• Positive Results in Ovarest® Clinical Trial for Endometriosis Treatment
• Positive Results in Ovarest® Endometriosis Trial
• Scientific Advisory Board
• Site Map
• Terms of Use
• Thank You
• Timothy J. Saxon

Posts by category

• Category: Uncategorized